Related Experiment Videos
Current and emerging serious Gram-positive infections
1Infectious Diseases Unit, Cisanello Hospital, 56100 Pisa, Italy. framenic@tin.it
Summary
New antimicrobial agents are urgently needed to combat drug-resistant Gram-positive pathogens like MRSA and VRE. Existing treatments are failing, necessitating novel solutions with improved safety and efficacy.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Serious Gram-positive bacterial infections are challenging to treat due to rising antimicrobial resistance.
- Key resistant pathogens include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and penicillin-resistant Streptococcus pneumoniae.
Purpose of the Study:
- To highlight the urgent clinical need for novel antimicrobial agents.
- To emphasize the requirement for agents with favorable pharmacokinetic and safety profiles.
- To address the growing challenge of Gram-positive pathogen resistance.
Main Methods:
- This study is a review of current challenges in treating Gram-positive infections.
- It analyzes emerging resistance patterns and treatment failures.
- It identifies criteria for new antimicrobial agents.
Main Results:
- Increasing resistance to established and newer antibiotics (e.g., linezolid) is reported.
- Emergence of vancomycin-intermediate and -resistant MRSA (VISA/VRSA) further limits therapeutic options.
- Clinical failures with current treatments are becoming more frequent.
Conclusions:
- There is a critical unmet need for new antimicrobial drugs.
- Future agents must demonstrate efficacy against resistant Gram-positive bacteria.
- Development should focus on suitable pharmacokinetic properties and safety profiles.